公开(公告)号：US11530413B2

公开(公告)日：2022-12-20

申请号：US16632777

申请日：2018-07-20

Applicant: NOVARTIS AG

Inventor： Eric Billy ,  Antoine De Weck ,  Javad Golji ,  Gregory Hoffman ,  Francesco Hofmann ,  Audrey Kauffmann ,  Konstantinos John Mavrakis ,  Earl Robert McDonald, III ,  William Sellers ,  Tobias Schmelzle ,  Frank Peter Stegmeier ,  Michael Ray Schlabach, Jr.

IPC: C12N15/115 ,  A61K45/06 ,  C12N9/22 ,  C12N15/113 ,  G01N33/574 ,  A61K47/18

Abstract: The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.

公开(公告)号：US10023862B2

公开(公告)日：2018-07-17

申请号：US14371131

申请日：2013-01-08

Applicant: Dieter Huesken ,  Brian Bettencourt ,  David Bumcrot ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Michael Schlabach, Jr. ,  Frank P. Stegmeier ,  Markus Warmuth ,  Jan Weiler ,  NOVARTIS AG

Inventor： Brian Richard Bettencourt ,  David Anton Bumcrot ,  Dieter Huesken ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Michael Ray Schlabach, Jr. ,  Frank Peter Stegmeier ,  Markus Warmuth ,  Jan Weiler

IPC: A61P35/00 ,  A61P17/02 ,  C12N15/113 ,  A61K31/713

Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.